Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monosialoganglioside - Qilu Pharmaceutical

Next Previous
X
Search
Drug Profile

Monosialoganglioside - Qilu Pharmaceutical

Alternative Names: GM 1 - Qilu Pharmaceutical; Monosialotetrahexose ganglioside sodium - Qilu Pharmaceutical

Latest Information Update: 24 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Gangliosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke
  • Preclinical Peripheral nervous system diseases

Most Recent Events

  • 30 Aug 2023 Qilu Pharmaceutical completes a phase-III trial in Stroke in China (IV), (NCT06742216)
  • 13 Apr 2023 Preclinical trials in Peripheral nervous system diseases (Prevention) in China (unspecified route)
  • 13 Apr 2023 Qilu Pharmaceutical plans a phase II/III trial in Peripheral nervous system diseases (Injection) (Prevention, In adults, in the elderly) (NCT05802342) in April 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top